Aytu BioPharma, Inc. – NASDAQ:AYTU

Aytu BioPharma stock price today

$2.16
+0.64
+42.11%
Financial Health
0
1
2
3
4
5
6
7
8
9

Aytu BioPharma stock price monthly change

-45.52%
month

Aytu BioPharma stock price quarterly change

-45.52%
quarter

Aytu BioPharma stock price yearly change

-48.99%
year

Aytu BioPharma key metrics

Market Cap
8.54M
Enterprise value
9.36M
P/E
-0.05
EV/Sales
0.08
EV/EBITDA
-0.13
Price/Sales
0.06
Price/Book
0.14
PEG ratio
N/A
EPS
-23.85
Revenue
98.90M
EBITDA
-77K
Income
-49.24M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-76.1%
Oper. margin
-21.22%
Gross margin
59.53%
EBIT margin
-21.22%
EBITDA margin
-0.08%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Aytu BioPharma stock price history

Aytu BioPharma stock forecast

Aytu BioPharma financial statements

Aytu BioPharma, Inc. (NASDAQ:AYTU): Profit margin
Jun 2022 27.44M -38.05M -138.65%
Mar 2023 22.73M -5.84M -25.7%
Jun 2023 30.73M -2.45M -7.99%
Mar 2024 17.99M -2.88M -16.05%
Aytu BioPharma, Inc. (NASDAQ:AYTU): Analyst Estimates
2026 71.57M 662K 0.92%
2027 117.7M -1.06M -0.91%
  • Analysts Price target

  • Financials & Ratios estimates

Aytu BioPharma, Inc. (NASDAQ:AYTU): Debt to assets
Dec 2022 141436000 95.61M 67.61%
Mar 2023 147216000 106.30M 72.21%
Jun 2023 136463000 97.10M 71.16%
Mar 2024 128863000 98.08M 76.12%
Aytu BioPharma, Inc. (NASDAQ:AYTU): Cash Flow
Jun 2022 -7.09M -41K -1.11M
Mar 2023 -2.90M 1K 2.58M
Jun 2023 9.36M -155K -5.40M
Mar 2024 -254K -45K 530K

Aytu BioPharma alternative data

Aytu BioPharma, Inc. (NASDAQ:AYTU): Employee count
Aug 2023 164
Sep 2023 164
Oct 2023 164
Nov 2023 150
Dec 2023 150
Jan 2024 150
Feb 2024 150
Mar 2024 150
Apr 2024 150
May 2024 150
Jun 2024 150
Jul 2024 150

Aytu BioPharma other data

12.19% -8.94%
of AYTU is owned by hedge funds
3.61M -1.96M
shares is hold by hedge funds

Aytu BioPharma, Inc. (NASDAQ:AYTU): Insider trades (number of shares)
Period Buy Sel
Nov 2022 312000 0
Dec 2022 212371 0
Jun 2023 26000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Common Shares 208 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Restricted Stock Units 208 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Common Shares 209 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Restricted Stock Units 209 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Common Shares 208 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commercial Officer
Restricted Stock Units 208 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commerical Officer
Common Shares 208 N/A N/A
Option
PYSZCZYMUKA GREG officer: Chief Commerical Officer
Restricted Stock Units 208 N/A N/A
Purchase
PYSZCZYMUKA GREG officer: Chief Commerical Officer
Common Shares 12,000 $1.87 $22,428
Purchase
DISBROW JOSHUA R. director, officer.. Common Shares 14,000 $1.86 $26,082
Tuesday, 3 December 2024
accesswire.com
Friday, 22 November 2024
accesswire.com
Wednesday, 13 November 2024
seekingalpha.com
accesswire.com
Wednesday, 6 November 2024
accesswire.com
Monday, 14 October 2024
accesswire.com
Tuesday, 1 October 2024
accesswire.com
Thursday, 26 September 2024
seekingalpha.com
accesswire.com
Thursday, 19 September 2024
accesswire.com
Thursday, 8 August 2024
accesswire.com
Tuesday, 6 August 2024
accesswire.com
Tuesday, 18 June 2024
accesswire.com
Wednesday, 15 May 2024
seekingalpha.com
accesswire.com
Wednesday, 8 May 2024
accesswire.com
Wednesday, 3 April 2024
Accesswire
Wednesday, 14 February 2024
Seeking Alpha
Wednesday, 7 February 2024
Accesswire
Tuesday, 14 November 2023
Seeking Alpha
Tuesday, 7 November 2023
Accesswire
Monday, 9 October 2023
Accesswire
Thursday, 28 September 2023
PennyStocks
Wednesday, 27 September 2023
Seeking Alpha
Thursday, 21 September 2023
Accesswire
Wednesday, 13 September 2023
Accesswire
Thursday, 11 May 2023
Seeking Alpha
Thursday, 4 May 2023
Accesswire
Tuesday, 21 February 2023
Seeking Alpha
Accesswire
  • What's the price of Aytu BioPharma stock today?

    One share of Aytu BioPharma stock can currently be purchased for approximately $2.16.

  • When is Aytu BioPharma's next earnings date?

    Unfortunately, Aytu BioPharma's (AYTU) next earnings date is currently unknown.

  • Does Aytu BioPharma pay dividends?

    No, Aytu BioPharma does not pay dividends.

  • How much money does Aytu BioPharma make?

    Aytu BioPharma has a market capitalization of 8.54M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24.58% to 81M US dollars.

  • What is Aytu BioPharma's stock symbol?

    Aytu BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "AYTU".

  • What is Aytu BioPharma's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Aytu BioPharma?

    Shares of Aytu BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Aytu BioPharma's key executives?

    Aytu BioPharma's management team includes the following people:

    • Mr. Joshua R. Disbrow Chairman & Chief Executive Officer(age: 50, pay: $1,010,000)
  • How many employees does Aytu BioPharma have?

    As Jul 2024, Aytu BioPharma employs 150 workers.

  • When Aytu BioPharma went public?

    Aytu BioPharma, Inc. is publicly traded company for more then 16 years since IPO on 25 Sep 2008.

  • What is Aytu BioPharma's official website?

    The official website for Aytu BioPharma is aytubio.com.

  • Where are Aytu BioPharma's headquarters?

    Aytu BioPharma is headquartered at 373 Inverness Parkway, Englewood, CO.

  • How can i contact Aytu BioPharma?

    Aytu BioPharma's mailing address is 373 Inverness Parkway, Englewood, CO and company can be reached via phone at +7 204376580.

Aytu BioPharma company profile:

Aytu BioPharma, Inc.

aytubio.com
Exchange:

NASDAQ

Full time employees:

102

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

373 Inverness Parkway
Englewood, CO 80112

CIK: 0001385818
ISIN: US0547548588
CUSIP: 054754874